AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$OMER

OMEROS CORP

Price · $OMERvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $OMER in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $OMER in the last 30 days.

Top stories · $OMERMore →
DEC 26·The Pharma LetterHigh

Omeros rockets as FDA approves Yartemlea

Omeros Corp (Nasdaq: OMER) shares surged 75.5% after the US FDA approved its drug Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Yartemlea is the first and only approved lectin pathway inhibitor for this often-fatal complication. The global market for complement-mediated thrombotic microangiopathy therapies reached $2.14 billion in 2024 and is projected to grow with a CAGR of 10.7%.

DEC 24·Stocktwits

Omeros Stock Garners High Retail Attention Ahead Of FDA Verdict For Life-Saving Drug

Omeros (OMER) stock is seeing significant retail attention ahead of an FDA decision on its drug Narsoplimab, a treatment for post-stem cell and bone marrow transplant complications, which is due on December 26, 2025. Stocktwits users are "extremely bullish" with high message volumes, anticipating FDA approval. The company recently sold Zaltenibart for $240 million upfront, bolstering its balance sheet and funding the planned U.S. launch of Narsoplimab.

News on $OMER